ES2765302T3 - Moléculas de ribotoxina derivadas de sarcina y otras ribotoxinas fúngicas relacionadas - Google Patents

Moléculas de ribotoxina derivadas de sarcina y otras ribotoxinas fúngicas relacionadas Download PDF

Info

Publication number
ES2765302T3
ES2765302T3 ES14775634T ES14775634T ES2765302T3 ES 2765302 T3 ES2765302 T3 ES 2765302T3 ES 14775634 T ES14775634 T ES 14775634T ES 14775634 T ES14775634 T ES 14775634T ES 2765302 T3 ES2765302 T3 ES 2765302T3
Authority
ES
Spain
Prior art keywords
sarcin
modified
epitope
mutation
wild
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14775634T
Other languages
English (en)
Spanish (es)
Inventor
Kurt Gehlsen
Timothy Jones
Francis Carr
Arron Hearn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Corp Tech Inc
Research Corp Technologies Inc
Original Assignee
Research Corp Tech Inc
Research Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp Tech Inc, Research Corp Technologies Inc filed Critical Research Corp Tech Inc
Application granted granted Critical
Publication of ES2765302T3 publication Critical patent/ES2765302T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/38—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Aspergillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
    • C12Y301/2701—Endoribonucleases producing 3'-phosphomonoesters (3.1.27) rRNA endonuclease (3.1.27.10)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES14775634T 2013-03-14 2014-03-03 Moléculas de ribotoxina derivadas de sarcina y otras ribotoxinas fúngicas relacionadas Active ES2765302T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361783589P 2013-03-14 2013-03-14
US201361902972P 2013-11-12 2013-11-12
PCT/US2014/020035 WO2014158770A1 (en) 2013-03-14 2014-03-03 Ribotoxin molecules derived from sarcin and other related fungal ribotoxins

Publications (1)

Publication Number Publication Date
ES2765302T3 true ES2765302T3 (es) 2020-06-08

Family

ID=51625052

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14775634T Active ES2765302T3 (es) 2013-03-14 2014-03-03 Moléculas de ribotoxina derivadas de sarcina y otras ribotoxinas fúngicas relacionadas

Country Status (11)

Country Link
US (2) US9603911B2 (enExample)
EP (1) EP2971038B1 (enExample)
JP (1) JP6203372B2 (enExample)
AU (1) AU2014241891B2 (enExample)
CA (1) CA2903252C (enExample)
DK (1) DK2971038T3 (enExample)
ES (1) ES2765302T3 (enExample)
PL (1) PL2971038T3 (enExample)
PT (1) PT2971038T (enExample)
SI (1) SI2971038T1 (enExample)
WO (1) WO2014158770A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903252C (en) * 2013-03-14 2023-01-17 Research Corporation Technologies, Inc. Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
WO2017053290A1 (en) * 2015-09-23 2017-03-30 Research Corporation Technologies, Inc. Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
EA202191610A1 (ru) * 2018-12-07 2021-10-25 Джиноум Протекшн, Инк. Композиции, полученные из сконструированного флагеллина, и их применение
WO2022038152A1 (en) * 2020-08-17 2022-02-24 Atb Therapeutics Recombinant immunotoxin comprising a ribotoxin or rnase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU654563B2 (en) * 1991-07-24 1994-11-10 Imperial Chemical Industries Plc Proteins
US8114969B2 (en) 2003-10-01 2012-02-14 Isis Innovation, Ltd. Immunotoxin derived from a recombinant human autoantibody and method of using thereof
EP1846432A4 (en) 2005-01-12 2008-11-19 Proteonova Inc METHOD FOR PRODUCING TARGETED THERAPEUTIC AGENTS
CA2903252C (en) * 2013-03-14 2023-01-17 Research Corporation Technologies, Inc. Ribotoxin molecules derived from sarcin and other related fungal ribotoxins

Also Published As

Publication number Publication date
EP2971038A4 (en) 2016-11-23
PT2971038T (pt) 2020-01-20
EP2971038B1 (en) 2019-12-04
JP6203372B2 (ja) 2017-09-27
PL2971038T3 (pl) 2020-04-30
US9976131B2 (en) 2018-05-22
CA2903252A1 (en) 2014-10-02
CA2903252C (en) 2023-01-17
WO2014158770A1 (en) 2014-10-02
JP2016512251A (ja) 2016-04-25
AU2014241891B2 (en) 2017-09-14
US20170204387A1 (en) 2017-07-20
EP2971038A1 (en) 2016-01-20
SI2971038T1 (sl) 2020-02-28
AU2014241891A1 (en) 2015-09-17
US9603911B2 (en) 2017-03-28
DK2971038T3 (da) 2020-01-27
US20160106819A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
CN111133002B (zh) 具有高体内耐受性的基于蒽环类药的抗体药物缀合物
ES2877356T3 (es) Epítopo de MHC de clase I que suministra polipéptidos
ES2847373T3 (es) Estructuras de subunidad A de toxina Shiga desinmunizadas y molécula de reconocimiento celular que las comprenden
ES3034413T3 (en) Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
US11976101B2 (en) Multi-level specific targeting of cancer cells
US11225509B2 (en) HER2-targeting molecules comprising de-immunized, Shiga toxin A subunit scaffolds
CN107750169A (zh) 包含蒽环类衍生物的结合蛋白药物缀合物
CN114828895A (zh) 制备基于艾日布林的抗体-药物缀合物的方法
US20200347113A1 (en) Epha3 and multi-valent targeting of tumors
US9976131B2 (en) Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
US20180028682A1 (en) Maytansine-drug conjugates of her-2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation
JP2025129192A (ja) 胆道癌の治療のための、her2を標的とする二重特異性抗原結合構築物の使用方法
WO2025027181A1 (en) Agents and methods for targeted delivery to cells
WO2017053290A1 (en) Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
HK40128270A (en) Methods of using a bispecific antigen-binding construct targeting her2 for the treatment of biliary tract cancers
WO2025247847A1 (en) A matriptase-cleavable substrate
HK40068270B (en) Methods of using a bispecific antigen-binding construct targeting her2 for the treatment of biliary tract cancers